Literature DB >> 9247253

Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease.

P W Chen1, T G Murray, T Uno, M L Salgaller, R Reddy, B R Ksander.   

Abstract

Primary melanomas that form within the eye have a unique pattern of disease progression as compared with melanomas that form within the skin. A high percentage of patients (approximately 50%) develop metastatic tumors that occur predominately in the liver. An unusual characteristic of ocular melanomas is the prolonged disease-free interval that extends for many years between the development of primary and metastatic tumors. It is estimated that the shortest interval between dissemination of tumor cells from the eye and the appearance of clinically detectable metastases is 6 years. A recent report indicated that fresh uveal melanoma tissue and metastatic tumor biopsies failed to express melanoma antigen gene (MAGE)-1, MAGE-2, or MAGE-3. In the present study, we examined the expression of MAGE genes on fresh and cultured tumor cells obtained from an ocular melanoma patient during different stages of progressive disease. MAGE gene expression was determined by reverse transcription-polymerase chain reaction using MAGE-1, MAGE-2 and MAGE-3 specific primers. Our results demonstrate that primary ocular tumor tissue and cultured tumor cells both express significant levels of MAGE-1, 2, and 3 at the time of enucleation. A high percentage of tumor cells within the primary tumor appear to express MAGE as demonstrated by consistent MAGE expression in 16 tumor cell clones. Metastatic liver tumors that developed 3 years after enucleation and 18 years after the initial formation of the primary tumor also expressed high levels of MAGE-1, -2, and -3. MAGE was expressed on fresh tumor tissue from a single biopsy and cultured tumor cells obtained from three of four different metastatic tumor nodules. When the MAGE-negative metastatic tumor cells were treated with the demethylating agent 5-Aza-2-Deoxycytidine (5-Aza-dC), transcription of MAGE-1 was restored, indicating the MAGE genes were not deleted. Our results demonstrate that in some patients, MAGE genes are expressed on primary and metastatic ocular melanomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9247253     DOI: 10.1023/a:1018479011340

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  26 in total

1.  A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.

Authors:  P van der Bruggen; J Bastin; T Gajewski; P G Coulie; P Boël; C De Smet; C Traversari; A Townsend; T Boon
Journal:  Eur J Immunol       Date:  1994-12       Impact factor: 5.532

2.  Expression of MAGE genes in primary and metastatic cutaneous melanoma.

Authors:  F Brasseur; D Rimoldi; D Liénard; B Lethé; S Carrel; F Arienti; L Suter; R Vanwijck; A Bourlond; Y Humblet
Journal:  Int J Cancer       Date:  1995-11-03       Impact factor: 7.396

3.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

4.  Expression of MAGE-1, MAGE-2, MAGE-3/-6 and MAGE-4a/-4b genes in ovarian tumors.

Authors:  A Yamada; A Kataoka; S Shichijo; T Kamura; Y Imai; T Nishida; K Itoh
Journal:  Int J Cancer       Date:  1995-12-20       Impact factor: 7.396

5.  Aqueous humor contains transforming growth factor-beta and a small (less than 3500 daltons) inhibitor of thymocyte proliferation.

Authors:  R D Granstein; R Staszewski; T L Knisely; E Zeira; R Nazareno; M Latina; D M Albert
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

Review 6.  Tumor antigens recognized by T lymphocytes.

Authors:  T Boon; J C Cerottini; B Van den Eynde; P van der Bruggen; A Van Pel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

7.  Identification of alpha-melanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor.

Authors:  A W Taylor; J W Streilein; S W Cousins
Journal:  Curr Eye Res       Date:  1992-12       Impact factor: 2.424

8.  Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.

Authors:  J Weber; M Salgaller; D Samid; B Johnson; M Herlyn; N Lassam; J Treisman; S A Rosenberg
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

9.  Studies of tumor-infiltrating lymphocytes from a human choroidal melanoma.

Authors:  B R Ksander; P E Rubsamen; K R Olsen; S W Cousins; J W Streilein
Journal:  Invest Ophthalmol Vis Sci       Date:  1991-12       Impact factor: 4.799

10.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

Authors:  C Traversari; P van der Bruggen; I F Luescher; C Lurquin; P Chomez; A Van Pel; E De Plaen; A Amar-Costesec; T Boon
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

View more
  28 in total

1.  Verteporfin induces apoptosis and eliminates cancer stem-like cells in uveal melanoma in the absence of light activation.

Authors:  Ya-Wen Ma; Yi-Zhi Liu; Jing-Xuan Pan
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

2.  PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.

Authors:  Gülçin Gezgin; Sietse J Luk; Jinfeng Cao; Mehmet Dogrusöz; Dirk M van der Steen; Renate S Hagedoorn; Daniëlle Krijgsman; Pieter A van der Velden; Matthew G Field; Gregorius P M Luyten; Karoly Szuhai; J William Harbour; Ekaterina S Jordanova; Mirjam H M Heemskerk; Martine J Jager
Journal:  JAMA Ophthalmol       Date:  2017-06-01       Impact factor: 7.389

3.  Uveal melanoma cell growth is inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase.

Authors:  Ahmad Al-Moujahed; Fotini Nicolaou; Katarzyna Brodowska; Thanos D Papakostas; Anna Marmalidou; Bruce R Ksander; Joan W Miller; Evangelos Gragoudas; Demetrios G Vavvas
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-29       Impact factor: 4.799

4.  Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters.

Authors:  Lata Singh; Mithalesh Kumar Singh; Maria Cristina Kenney; Martine J Jager; Moshahid Alam Rizvi; Rachna Meel; Neiwete Lomi; Sameer Bakhshi; Seema Sen; Seema Kashyap
Journal:  Cancer Immunol Immunother       Date:  2020-11-02       Impact factor: 6.968

5.  Tight junction-associated signaling pathways modulate cell proliferation in uveal melanoma.

Authors:  Ashwath Jayagopal; Jin-Long Yang; Frederick R Haselton; Min S Chang
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-01       Impact factor: 4.799

Review 6.  Uveal Melanoma Cell Lines: Where do they come from? (An American Ophthalmological Society Thesis).

Authors:  Martine J Jager; J Antonio Bermudez Magner; Bruce R Ksander; Sander R Dubovy
Journal:  Trans Am Ophthalmol Soc       Date:  2016-08

Review 7.  Embryonic Zebrafish: Different Phenotypes after Injection of Human Uveal Melanoma Cells.

Authors:  Wietske van der Ent; Claudia Burrello; Mark J de Lange; Pieter A van der Velden; Aart G Jochemsen; Martine J Jager; B Ewa Snaar-Jagalska
Journal:  Ocul Oncol Pathol       Date:  2015-04-09

8.  Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.

Authors:  Armelle Calipel; Solange Landreville; Arnaud De La Fouchardière; Frédéric Mascarelli; Michel Rivoire; Nicolas Penel; Frédéric Mouriaux
Journal:  Clin Exp Metastasis       Date:  2014-03-21       Impact factor: 5.150

9.  Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.

Authors:  Nabil Amirouchene-Angelozzi; Fariba Nemati; David Gentien; André Nicolas; Amaury Dumont; Guillaume Carita; Jacques Camonis; Laurence Desjardins; Nathalie Cassoux; Sophie Piperno-Neumann; Pascale Mariani; Xavier Sastre; Didier Decaudin; Sergio Roman-Roman
Journal:  Mol Oncol       Date:  2014-06-13       Impact factor: 6.603

10.  Epigenetic regulation of CXCR4 expression by the ocular microenvironment.

Authors:  Haochuan Li; Jerry Y Niederkorn; Leila Sadegh; Jessamee Mellon; Peter W Chen
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-09       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.